Rebecca R. Roylance - Publications

Safety of withdrawal of pharmacological treatment after recovery from HER2 therapy-related cardiac dysfunction: the HER-SAFE trial.

Journal: European heart journal

Published: July 06, 2026

A Five-Year Retrospective Analysis of Neoadjuvant Therapy in Early-Stage Breast Cancer: Subtype Outcomes and Imaging Concordance.

Journal: The breast journal

Published: October 15, 2025

Completion vs. early discontinuation of chemotherapy and the impact on 5-year all-cause mortality in women treated for early-stage breast cancer from 2015 to 2020: A cohort study using a target trial emulation approach.

Journal: British journal of clinical pharmacology

Published: September 30, 2025

The safety and clinical impact of ultra-low-dose FDG-PET imaging in pregnancy-associated breast cancer: the experience of a major tertiary oncology referral centre in the UK and suggested imaging protocol.

Journal: Nuclear medicine communications

Published: June 04, 2025

Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease.

Journal: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Published: April 04, 2025

HER-SAFE study design: an open-label, randomised controlled trial to investigate the safety of withdrawal of pharmacological treatment for recovered HER2-targeted therapy-related cardiac dysfunction.

Journal: BMJ open

Published: February 05, 2025

Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.

Journal: Nature communications

Published: October 25, 2024

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].

Journal: ESMO open

Published: July 15, 2024

Regional differences in neo/adjuvant chemotherapy timing in patients with early-stage triple-negative breast cancer in England.

Journal: Breast cancer research and treatment

Published: June 21, 2024

The impact of inter-cycle treatment delays on 5-year all-cause mortality in early-stage breast cancer: A retrospective cohort study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 17, 2024

The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 04, 2024

The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.

Journal: Nature

Published: February 06, 2024